Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China-Reference-Cited by-同舟云学术

Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China

Published:2024-04-11 Issue:5 Volume:24 Page:671-678
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Li Wei¹^ORCID,Wan Li¹

Affiliation:

1. Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2341859

Reference43 articles.

1. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. In: China cancer incidence and mortality 2022. Lyon, France: International Agency for Research on Cancer; 2020 [cited 2024 Apr 11]. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf

2. Stomach cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study

3. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

4. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

5. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the therapeutic effect of sintilimab combined with modified DCF regimen on advanced gastric cancer and its impact on Th1/Th2 immune balance;Anti-Cancer Drugs;2024-06-28